Updated:
Mochida Pharmaceutical
Naoyuki Mochida directs Japan's century-old public pharma company, which co-invests alongside Itochu and funds medical research through its own foundation.
Overview
Mochida Pharmaceutical is a healthcare company that specializes in the sales of pharmaceuticals, skincare products, and diagnostics.
General information
Firm type
Corporate Investor
Year founded
1913
Location
Region
Asia
Country
Japan
City
Tokyo
Corporate office
7, Yotsuya 1-chome, Shinjuku-ku, Tokyo 160-8515, Japan
Additional offices
Gotemba, Shizuoka, Japan · Ohtawara, Tochigi, Japan
Principals
Naoyuki Mochida
President and CEO
Sector focus
Frequently asked questions
Who controls investment decisions at Mochida Pharmaceutical?
President and CEO Naoyuki Mochida exercises primary control, backed by his 2.88% equity stake. The Mochida family collectively holds over 5% through Naoyuki and Takeshi Mochida's positions, while Taisho Pharmaceutical owns 2.26%. Strategic decisions therefore balance family influence with public-company governance.
Does Mochida Pharmaceutical make direct investments or fund commitments?
The firm makes direct co-investments, as evidenced by its joint venture And Pharma Co., Ltd. with Itochu Corporation. There is no public record of the company acting as a limited partner in third-party venture funds or committing to external pooled vehicles.
Which therapeutic areas does the firm target with its investment capital?
Deployment aligns with the parent company's R&D pipeline: specialty pharmaceuticals, women's health, and central nervous system disorders. Co-investments like And Pharma center on drug development within these therapeutic categories rather than diversified stage-agnostic dealmaking.
How is the Mochida Memorial Foundation separated from the company's commercial activities?
The Mochida Memorial Foundation for Medical and Pharmaceutical Research functions as an independent grant-making entity supporting early-career Japanese scientists. It operates separately from the company's for-profit co-investment and manufacturing activities, though both draw from the same corporate origin.
Does the firm co-invest along with other pharmaceutical corporates?
Yes. Itochu Corporation co-invested with Mochida in And Pharma Co., Ltd. Taisho Pharmaceutical also holds a material equity stake in Mochida itself, creating a web of cross-holdings that can facilitate shared due diligence among Japanese pharma players.
Profile maintained by Altss. Updated: . To correct this record or make a privacy request, send the page URL and your evidence to privacy@altss.com; corrections are free.
Need institutional-grade insight on investors?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: